Martin Maron, MD
Enriched profileDirector, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center · Lahey Hospital & Medical Center
Martin Maron is Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center at Lahey Hospital & Medical Center. OpenAlex indexes 576 publications with 39,531 citations (h-index 93); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Martin S. Maron, MD, is Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center. The public record shows 576 publications with 39,531 citations (h-index 93), centered on Heart Failure. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 11 companies, 3 NIH-funded awards (2007–2026).
- Most recent indexed publication: 2026 · Journal of the American Heart Association
- Top research focus: Heart Failure
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Extended ECG Monitoring in HCM Patients
Sponsor: iRhythm Technologies, Inc.
- Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Sponsor: Tufts Medical Center
Industry payments
Updated 27 Aug 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Amicus Therapeutics, Inc.Program year20251 payment
- Alexion Pharmaceuticals, Inc.Program year20253 payments
- Novo Nordisk ASProgram year20252 payments
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
61.5%Beta blocker49.5%Metoprolol Succinate100%Part D≥17 patientsCalcium channel blocker11.9%Verapamil Er100%Part D<11 patientsBlood & clotting
25.7%Factor Xa inhibitor25.7%Eliquis100%Part D<11 patientsNervous system
12.8%Other nervous system drugs12.8%Vyndamax100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMR
Beth Israel Deaconess Medical Center
FY2026$725,029R01HL177076 - Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMR
Beth Israel Deaconess Medical Center
FY2025$777,258R01HL177076 - Cardiac MR-Based Risk Stratification for Heart Failure and Atrial Fibrillation in HCM
Beth Israel Deaconess Medical Center
FY2024$675,466R01HL158098
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.
Journal of the American Heart Association
Article2026 - Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies.
Journal of the American Heart Association
Review2026 - Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data.
Journal of the American Heart Association
Article2026 - Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.
Circulation. Heart failure
Clinical Trial2026 - Myocardial Entropy and Risk Predictors in Hypertrophic Cardiomyopathy: An Analysis From the NHLBI HCM Registry.
Circulation. Cardiovascular imaging
Article2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/martin-maron-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/martin-maron
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
profiles.umassmed.edu/display/55567359
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.umassmed.edu ↗
Mentions by others
where others cite or feature them- Other
hcmbeat.com/2021/09/26/cytokinetics-drug-aficamten-upcoming-hcm-summit-interview-with-dr-martin-maron
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcmbeat.com ↗ - Other
thehcmacademy.com/faculty/martin-maron
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thehcmacademy.com ↗ - Other
hcplive.com/view/understanding-aficamten-and-the-sequoia-hcm-design-with-martin-maron-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Board Certified
Cardiovascular Disease and Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Steering Committee
HCM Academy faculty
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thehcmacademy.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hearteducationusa.com ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor of Medicine
Tufts University School of Medicine; former Director, Hypertrophic Cardiomyopathy Program, Tufts Medical Center (Boston, MA), for approximately 20 years prior to moving to Lahey
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Media & interviews
press, podcasts and appearances- "Martin S. Maron, MD | Hypertrophic Cardiomyopathy in 2025"
Texas Heart Institute Cardiology Grand Rounds 2024-25 video lecture
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tv.texasheart.org ↗ - "Diagnosing and Managing Hypertrophic Cardiomyopathy: A Conversation with Dr. Martin Maron"
Texas Heart Institute "Inside the Studio" video interview
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tv.texasheart.org ↗ - Presenter
Episode 7 "Invasive Strategies: Percutaneous and Surgical", American Heart Association Hypertrophic Cardiomyopathy podcast series
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →professional.heart.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.